



Biotech Daily

Wednesday August 6, 2014

Daily news on ASX-listed biotechnology companies

- * ASX, BIOTECH DOWN: ONCOSIL UP 14%, ANTEO DOWN 11%**
- * PALADIN LAUNCHES IMMURON'S TRAVELAN IN CANADA**
- * LIFE SCIENCES QLD, TRANSLATIONAL RESEARCH CONFERENCE**
- * REGENEUS REQUESTS \$6m CAPITAL RAISING TRADING HALT**

MARKET REPORT

The Australian stock market slipped 0.12 percent on Wednesday August 6, 2014 with the S&P ASX 200 down 6.6 points to 5,512.0 points.

Eleven of the Biotech Daily Top 40 stocks were up, 15 fell, nine traded unchanged and five were untraded.

Oncosil was the best, up 1.5 cents or 14.3 percent to 12 cents with 473,333 shares traded.

Osprey climbed 6.9 percent; Acrux was up 4.5 percent; Antisense was up 3.7 percent; Benitec, Cochlear, Ellex and Neuren rose more than two percent; GI Dynamics, Phosphagenics and Starpharma were up more than one percent; with Alchemia up 0.9 percent.

Anteo led the falls, down 1.5 cents or 10.7 percent to 12.5 cents with 13.5 million shares traded.

Circadian lost 7.7 percent; Atcor, Biotron, Clinuvel, Medical Developments, Prana and Prima fell more than four percent; Patrys was down 3.45 percent; Analytica, Bionomics and Mesoblast shed more than two percent; CSL and Pharmaxis lost more than one percent; with Nanosonics, Resmed and Sirtex down by less than one percent.

IMMURON

Immuron says its Canada partner Paladin Labs has launched its bovine colostrum-based diarrhoea preventative Travelan in Canada.

Immuron said that there were more than five million trips made by Canadians to at-risk regions every year and one third of Canadian vacationers had experienced or travelled with someone who experienced travellers' diarrhoea.

The company said that three-quarters of Canadians had indicated that they would take a preventive for travellers' diarrhoea.

Immuron said that the Paladin agreement included an upfront payment and milestone payments based on Paladin's commercialization success, which were in addition to the transfer price payable for each unit of product sold by Immuron to Paladin.

Immuron chief executive officer Amos Meltzer said the company was "of course, very pleased with Paladin's launch".

"Paladin has a proven track record in successfully marketing and selling a range of over-the-counter products and we are confident that Paladin is well placed to take advantage of Travelan's potential in Canada," Mr Meltzer said.

Immuron was unchanged at half a cent with 7.5 million shares traded.

LIFE SCIENCES QUEENSLAND, TRANSLATIONAL RESEARCH INSTITUTE

Life Sciences Queensland says its October 24, 2014 biennial conference on translational research, TRX14, has opened for registration.

Life Sciences Queensland said that the conference will be held at the home of the major sponsor, Brisbane's Translational Research Institute.

The industry organization said that the event "aims to enhance standards for the medical industry by stimulating trans-disciplinary collaborations across human disease research, drug and diagnostic discovery and development, [information technology] and bioinformatics".

Life Sciences Queensland chief executive officer Mario Pennisi said the event would bring together stakeholders from the life sciences industry, investment community, academia and government, alongside speakers to reflect the broad spectrum of facets that comprise the medical and translational research industry.

"TRX14 will feature national and international speakers across [research and development], the regulatory environment and quality systems practices, medical publishing, intellectual property, commercialization and change implementation," Mr Pennisi said.

"The symposium aims to stimulate discussion and collaboration amongst key stakeholders to enhance research outcomes and create value through the translation of data into knowledge and benefits," Mr Pennisi said.

Life Sciences Queensland said that confirmed speakers included Australian Therapeutic Goods Administration chief executive officer Prof John Skerritt, Translational Research Institute director Prof Ian Frazer, Novartis executive Dr Stephen Volsen, Healthcare ventures investment manager Doug Onsi, Queensland Institute of Medical Research Berghofer director Prof Frank Gannon; Cooperative Research Centre Association chief executive officer Dr Tony Peacock and the National Foundation for Medical Research and Innovation chief executive officer Dr Noel Chambers.

The conference will be held at the Translational Research Institute, 37 Kent St, Woolloongabba, adjacent to the Princess Alexandra Hospital.

For more information and to register go to: www.trx14.com.au.

REGENEUS

Regeneus has requested a trading halt pending an announcement to the market in relation to a potential capital raising”.

Trading will resume on August 8, 2014 or on an earlier announcement.

Separately, Pelaton Capital said that Regeneus hoped to raise up to \$3 million in a placement at 26 cents a share and a further \$3 million in a share purchase plan at the same price.

Pelaton Capital said that there would be one-for-three free attaching options exercisable at 40 cents each within 12 months of issue.

Regeneus last traded at 28.5 cents.